Description

The participants focus on the topic of managing recurrent bleeding due to small-intestinal angiodysplasia – a persistent challenge encountered by many hepatologists. Our panel explores effective treatments and interventions, including medications like bevacizumab and thalidomide, alongside the role of endoscopy in diagnosis and management.

Faculty

• Pierre-Emmanuel Rautou (Moderator)
• Virginia Hernández-Gea (Faculty)
• Patrick Kamath (Faculty)
• Wim Laleman (Faculty)

Related episodes:

• EASL Studio S2E6: Should anticoagulants be given to patients with cirrhosis to improve outcome?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In this exclusive session, Thomas Berg and his panelists examine the intricate world of intrahepatic Cholangiocarcinoma (iCCA), following the publication of the EASL clinical practice guidelines on iCCA in 2023. This discussion aim at raising awareness and promoting a deeper understanding of this complex condition, while touching upon the topic of targeted therapies, highlighting the advancements and challenges that lie ahead.

Faculty

• Thomas Berg (Moderator)
• Katie Kelley (Faculty)
• Daniela Sia (Faculty)
• Juan Valle (Faculty)

This episode is scheduled in honour of the World CCA Day (15 February) and the US CCA Awareness Month.

Related episodes

• EASL Studio S5E13: Basics in decision-making for liver cancer treatment
• EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
• EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
• EASL Studio S4 Special Edition 1: A new strategy for liver cancer screening: EASL Policy Statement on risk-based surveillance
• EASL Studio S3E16: Liver cancer in 2022: Wrap-up & outlook
• EASL Studio S3E8: Transplanting patients with cancer – Is there a limit?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Description

In this episode, the panellists evaluate past efforts, current trials, and the evolving landscape of HBV cure research. They also weigh the patient-friendliness of these strategies, exploring potential pathways to a cure. How will the landscape of trials and research methodologies evolve in the future to facilitate this quest?

Faculty

• Ahmed Elsharkawy (Moderator)
• Markus Cornberg (Faculty)
• Dickens Theodore (GSK Representative)
• Su Wang (Faculty)

This EASL Studio is supported by GSK.

Related episodes:

• EASL Studio from EASL Congress 2023: The bumpy road of Hepatitis B drug development successes and challenges
• EASL Studio S4E1: Hepatitis B elimination: how far behind are we and what do we need to change to achieve it?
• EASL Studio S3E9: JHEP Live: Antisense oligonucleotides vs. siRNAs in the treatment of chronic hepatitis B —Who will be the winner, if at all?
• EASL Studio from ILC 2022: HBV/HDV Roundtable: HBV and HDV drug development – Where do we stand and where are we going?

ℹ️ Please click here to access the podcast version of this EASL Studio episode.